Product theaters provide time for presentation of new research findings on products, showcasing of product details, demonstrations and highlights of new products. These sessions may be promotional or non-promotional but are not eligible for continuing education credits. 

All industry events feature a meal or refreshment break served 15 minutes before the session start time in Centennial I.

Monday, April 17, 3:45 PM (CDT)

A refreshment break will be served from 4:30-4:45 PM Eastern in Centennial I, immediately before the program.

Learn More and Register

Using Rapid Clozapine Blood Levels to Improve Patient Management

Clozapine is the only evidence-based antipsychotic option for treatment-resistant schizophrenia and patients with schizophrenia and suicidality. However, using it demands regular monitoring of a patients' clozapine blood level. The faculty will discuss how a rapid clozapine blood level can improve managing patients' care and how to interpret values against the patient's response and tolerability. Professor Taylor will share his 30 years of experience working with clozapine, implementing a rapid clozapine blood test and blood level guidance that he provides within the South London and Maudsley Trust.
An open microphone session will follow the presentations.


Professor David Taylor, PhD, FRPharmS, FRCPsych(Hon)
Director of Pharmacy and Pathology
South London and Maudsley NHS Foundation Trust, London, UK
Professor of Psychopharmacology
Institute of Pharmaceutical Science, King’s College, London, UK
Therapeutic Advances in Psychopharmacology
Jonathan G. Leung, PharmD, BCPS, BCPP
Department of Pharmacy, Mayo Clinic, Rochester, MN

Megan Ehret, PharmD, MS, BCPP
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
SMI Adviser, Pharmacist Consultant

Supported by






















Tuesday, April 18, 10:30 AM (CDT)

Lunch will be served from 11:15-11:30 AM Eastern in Centennial I, immediately before the program.

Learn More and Register

Forging a New Path: Targeting Muscarinic Receptor Circuits in Schizophrenia

Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on an evolving class of investigational therapeutics that have shown great promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain. 

Learning Objectives

  1. Illustrate the evolving understanding of the psychopharmacology of schizophrenia with respect to muscarinic receptor–based mechanisms of action
  2. Introduce muscarinic receptor–modulating therapeutics currently under investigation for use in schizophrenia with a focus on muscarinic agonists
  3. Demonstrate how modulating muscarinic receptor activity may play a role in treating schizophrenia


Jose Rey, MS, PharmD, BCPP
Professor, Department of Pharmacy Practice
College of Pharmacy - Nova Southeastern University
Ft. Lauderdale, Florida

Clinical Psychopharmacologist
South Florida State Hospital – Wellpath Recovery Solutions
Pembroke Pines, Florida



Judith Kando, PharmD, BCPP

Supported by